Financial Counselors Inc. Purchases 4,680 Shares of Boston Scientific Corporation (NYSE:BSX)

Financial Counselors Inc. boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 63.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,048 shares of the medical equipment provider's stock after buying an additional 4,680 shares during the period. Financial Counselors Inc.'s holdings in Boston Scientific were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Bank Pictet & Cie Europe AG grew its stake in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in Boston Scientific by 18.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after buying an additional 6,264 shares in the last quarter. Blue Trust Inc. grew its stake in Boston Scientific by 13.0% in the 1st quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock valued at $504,000 after buying an additional 575 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its stake in Boston Scientific by 109.9% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 270,107 shares of the medical equipment provider's stock valued at $24,126,000 after buying an additional 141,398 shares in the last quarter. Finally, Little House Capital LLC purchased a new position in Boston Scientific in the 1st quarter valued at approximately $945,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BSX. Morgan Stanley raised their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Wall Street Zen raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Robert W. Baird raised their price target on shares of Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Leerink Partners started coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target for the company. Finally, Royal Bank Of Canada lifted their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Twenty-two analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Trading Up 0.7%

Shares of NYSE BSX traded up $0.77 during midday trading on Thursday, hitting $103.73. 1,993,759 shares of the company traded hands, compared to its average volume of 7,627,092. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. The stock has a 50-day moving average price of $103.45 and a 200 day moving average price of $100.35. The firm has a market cap of $153.46 billion, a P/E ratio of 75.73, a P/E/G ratio of 2.66 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. During the same quarter in the previous year, the company earned $0.56 earnings per share. Boston Scientific's quarterly revenue was up 20.9% on a year-over-year basis. As a group, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president owned 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,970 shares of company stock valued at $47,755,193. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.